THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Kenneth Berlin to Bridged Bicyclo Compounds, Heterocyclic

This is a "connection" page, showing publications Kenneth Berlin has written about Bridged Bicyclo Compounds, Heterocyclic.
  1. Electrophysiologic actions of d,l-sotalol and GLG-V-13 in ischemically injured canine epicardium. J Cardiovasc Pharmacol. 2007 Sep; 50(3):304-13.
    View in: PubMed
    Score: 0.292
  2. 7-Benzyl-3-thia-7-azabicyclo[3.3.1]nonane 3-oxide. Acta Crystallogr C. 1996 Apr 15; 52 ( Pt 4):995-8.
    View in: PubMed
    Score: 0.133
  3. The acute and subchronic toxicity of BRB-I-28, a novel class Ib antiarrhythmic agent, in CD-1 mice. Food Chem Toxicol. 2000 Sep; 38(9):817-23.
    View in: PubMed
    Score: 0.045
  4. Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in mice. Arzneimittelforschung. 2000 Jan; 50(1):31-8.
    View in: PubMed
    Score: 0.043
  5. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem. 1999 Oct 21; 42(21):4434-45.
    View in: PubMed
    Score: 0.042
  6. Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate. J Med Chem. 1996 Jun 21; 39(13):2559-70.
    View in: PubMed
    Score: 0.034
  7. Pharmacokinetics and plasma protein binding of the new potent class III antiarrhythmic agent 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3.1]nonane dihydroperchlorate. Arzneimittelforschung. 1995 Jun; 45(6):670-5.
    View in: PubMed
    Score: 0.031
  8. Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent. Eur J Drug Metab Pharmacokinet. 1995 Apr-Jun; 20(2):151-61.
    View in: PubMed
    Score: 0.031
  9. Electrophysiological characterization of a novel class III antiarrhythmic agent, GLG-V-13 in the mammalian heart. Acta Physiol Hung. 1995; 83(1):13-30.
    View in: PubMed
    Score: 0.030
  10. Effects of novel antiarrhythmic agents, BRB-I-28 and its derivatives, on the heart mitochondrial respiratory chain and sarcoplasmic reticulum Ca(2+)-ATPase. Res Commun Mol Pathol Pharmacol. 1994 Aug; 85(2):193-208.
    View in: PubMed
    Score: 0.030
  11. Electrophysiologic actions of BRB-I-28 in ischemically injured canine myocardium. J Cardiovasc Pharmacol. 1993 Apr; 21(4):637-46.
    View in: PubMed
    Score: 0.027
  12. The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heart. Acta Physiol Hung. 1993; 81(3):289-99.
    View in: PubMed
    Score: 0.026
  13. High-performance liquid chromatographic determination of BRB-I-28, a novel antiarrhythmic agent, in dog plasma and urine. J Chromatogr. 1992 Dec 02; 583(2):274-9.
    View in: PubMed
    Score: 0.026
  14. Effects of BRB-I-28, a novel antiarrhythmic agent, and its derivatives on cardiac Na+,K(+)-ATPase, Mg(2+)-ATPase activities and contractile force. Res Commun Chem Pathol Pharmacol. 1992 Oct; 78(1):3-16.
    View in: PubMed
    Score: 0.026
  15. Electrophysiological actions of BRB-I-28 in canine myocardial tissues. J Pharmacol Exp Ther. 1991 Nov; 259(2):558-65.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES